Literature DB >> 11166921

Genomic structure and loss of heterozygosity of EPHB2 in colorectal cancer.

S M Oba1, Y J Wang, J P Song, Z Y Li, K Kobayashi, S Tsugane, G S Hamada, M Tanaka, H Sugimura.   

Abstract

EphB2, a member of the Eph receptor protein-tyrosine kinase family, is overexpressed in several human gastrointestinal tumors. Furthermore, the EphB2 gene is localized at 1p35-p36.1, a frequently deleted region in colon and other cancers. So, despite its overexpression in some kind of tumors, we decided to study the possibility of involvement in the EphB2 gene (EPHB2) mutation in colon cancers, because some of the well known tumor suppressor genes (e.g. p53) is overexpressed (really accumulated) in tumors. Fifty colon tumor samples of matched with their respective normal tissues, were studied for mutation of the EPHB2. Analysis of the genomic structure of EphB2 and survey of all 16 exons revealed an infrequent polymorphism (intron 2) and mutation (intron 8). Another polymorphism in exon 6, localized at nucleotide 1359 (A-->G) was found to be rather frequent in Japanese and Chinese subjects, but very rare in Caucasians. Taking advantage of this polymorphism within EPHB2, we surveyed the loss of heterozygosity (LOH) status of this gene in Japanese colorectal tumors. Among the 50 samples analyzed, 24 were informative, and LOH was found in five of the15 (33.3%) informative rectal cancer cases. Mutation analysis covering all 16 exons in the remaining allele did not reveal any mutations. Thus, EPHB2 is not a classical tumor suppressor gene.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11166921     DOI: 10.1016/s0304-3835(00)00716-3

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  17 in total

Review 1.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond.

Authors:  Elena B Pasquale
Journal:  Nat Rev Cancer       Date:  2010-03       Impact factor: 60.716

Review 2.  Ependymomas: development of immunotherapeutic strategies.

Authors:  Ian F Pollack; Regina I Jakacki; Lisa H Butterfield; Hideho Okada
Journal:  Expert Rev Neurother       Date:  2013-10       Impact factor: 4.618

3.  Expression of Eph A4, Eph B2 and Eph B4 receptors in AML.

Authors:  Tomasz Wrobel; Joanna Pogrzeba; Ewa Stefanko; Marcin Wojtowicz; Bozena Jazwiec; Justyna Dzietczenia; Grzegorz Mazur; Kazimierz Kuliczkowski
Journal:  Pathol Oncol Res       Date:  2014-04-25       Impact factor: 3.201

4.  EphB1 Suppression in Acute Myelogenous Leukemia: Regulating the DNA Damage Control System.

Authors:  K R Kampen; F J G Scherpen; G Garcia-Manero; H Yang; G J L Kaspers; J Cloos; C M Zwaan; M M van den Heuvel-Eibrink; S M Kornblau; E S J M De Bont
Journal:  Mol Cancer Res       Date:  2015-05-05       Impact factor: 5.852

5.  Reduced expression of EphB2 is significantly associated with nodal metastasis in Chinese patients with gastric cancer.

Authors:  Guanzhen Yu; Yunshu Gao; Canrong Ni; Ying Chen; Jun Pan; Xi Wang; Zhiwei Ding; Jiejun Wang
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-18       Impact factor: 4.553

6.  EPH-EPHRIN in human gastrointestinal cancers.

Authors:  Haruhiko Sugimura; Jian-Dong Wang; Hiroki Mori; Masaru Tsuboi; Kiyoko Nagura; Hisaki Igarashi; Hong Tao; Ritsuko Nakamura; Hiroko Natsume; Tomoaki Kahyo; Kazuya Shinmura; Hiroyuki Konno; Yasushi Hamaya; Shigeru Kanaoka; Hideki Kataoka; Xiao-Jun Zhou
Journal:  World J Gastrointest Oncol       Date:  2010-12-15

Review 7.  The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.

Authors:  Jill Wykosky; Waldemar Debinski
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

8.  ALL1 fusion proteins induce deregulation of EphA7 and ERK phosphorylation in human acute leukemias.

Authors:  Hiroshi Nakanishi; Tatsuya Nakamura; Eli Canaani; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-28       Impact factor: 11.205

Review 9.  Immunotherapeutic approaches for glioma.

Authors:  Hideho Okada; Gary Kohanbash; Xinmei Zhu; Edward R Kastenhuber; Aki Hoji; Ryo Ueda; Mitsugu Fujita
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

10.  Expression of Ephb2 and Ephb4 in breast carcinoma.

Authors:  Qinghua Wu; Zhenhe Suo; Bjørn Risberg; Mats G Karlsson; Kenneth Villman; Jahn M Nesland
Journal:  Pathol Oncol Res       Date:  2004-03-18       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.